Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
Last trade$0.3354
Day change-$0.0646 (-16.15%)
Day range$0.327 – $0.415
Volume1,833,227
Market cap$35M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$34.51M
Price / earnings
—
Price / book
3.38×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.25×
Profitability
Earnings per share
-$0.58
Return on assets
-75.43%
Return on equity
-487.9%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.27×
Quick ratio
4.27×
Cash ratio
0.88×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$18.83M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RNTX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Revenue
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.44M
$2.16M
$1.96M
$3.81M
$2.58M
$2.56M
Research and development
$3.64M
$3.07M
$2M
$1.68M
$4.29M
$3.05M
Total operating expenses
$6.08M
$5.23M
$32.66M
$5.49M
$6.87M
$5.61M
Operating income
-$6.08M
-$5.23M
-$32.66M
-$5.49M
-$6.87M
-$5.61M
Interest expense
$0
$0
$0
$0
$0
$0
Income before taxes
-$6.38M
-$5.84M
-$32.68M
-$5.58M
-$6.82M
-$5.5M
Income taxes
$0
$0
-$712K
$0
$0
$0
Net income
-$6.38M
-$5.84M
-$31.97M
-$5.58M
-$6.82M
-$5.5M
Net income attributable to common shareholders
-$6.38M
-$5.84M
-$31.97M
-$5.58M
-$6.82M
-$5.5M
EBITDA
-$6.08M
-$5.23M
-$3.96M
-$5.49M
-$6.87M
-$5.61M
Basic earnings per share
-$0.10
-$0.19
-$1.09
-$0.21
-$0.28
-$0.25
Diluted earnings per share
-$0.10
-$0.19
-$1.09
-$0.21
-$0.28
-$0.25
Recent news
Company coverage with links to the original publishers.
Rein Therapeutics completed a $57.5 million underwritten public offering of common stock, including full exercise of the over-allotment option. The company will use net proceeds to fully fund its Phase 2 RENEW trial of LTI-03 for idiopathic pulmonary fibrosis and support operations into Q1 2028. The offering was backed by healthcare-focused investors including Adar1 Capital Management, Ikarian Capital, and Bios Partners.
Rein Therapeutics priced a public offering of 50 million shares at $1.00 per share, raising $50 million in gross proceeds. The company plans to use net proceeds to fully fund its Phase 2 clinical trial of LTI-03 for idiopathic pulmonary fibrosis and for working capital. Based on current operating plans, the company believes the proceeds combined with existing cash will fund operations into 2028.
The idiopathic pulmonary fibrosis (IPF) treatment landscape is expanding with 80+ companies developing 100+ novel therapies across various clinical stages. Growing disease awareness and diagnostic improvements are driving demand for more effective treatments beyond current antifibrotic limitations. Key developments include orphan drug designations, positive clinical trial data, and FDA clinical hold lifts for several promising candidates in 2025-2026.
Rein Therapeutics received UK regulatory approval to launch a Phase 2 clinical trial for LTI-03, a potential breakthrough treatment for idiopathic pulmonary fibrosis (IPF), targeting fibrosis and lung tissue regeneration.
Rein Therapeutics will present two scientific talks at the IPF Summit 2025, discussing their novel approach to treating idiopathic pulmonary fibrosis (IPF) through innovative molecular research and clinical trial design.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.